Personalising treatments for people with AML

Lead researcher - Dr James Allan, Newcastle University
The molecular genetics of acute myeloid leukaemia - stratified medicine to improve patient outcome
Amount awarded: £1,208,349
Award start date: 01 Apr 2014
Award duration: 6.5 years

Acute myeloid leukaemia (AML) is primarily a disease of the elderly and many patients cannot tolerate standard chemotherapy. In order to circumvent this problem we will investigate methods for using existing therapies more strategically based on patient and leukaemia characteristics, termed “stratified medicine.” We will also establish a pipeline for developing novel therapies that take advantage of specific defects in leukaemia cells to make them more vulnerable to chemotherapy. These approaches will identify components of cells that could then be targeted using specific inhibitors through Newcastle’s Drug Development Programme.